JP2003525944A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003525944A5 JP2003525944A5 JP2001565369A JP2001565369A JP2003525944A5 JP 2003525944 A5 JP2003525944 A5 JP 2003525944A5 JP 2001565369 A JP2001565369 A JP 2001565369A JP 2001565369 A JP2001565369 A JP 2001565369A JP 2003525944 A5 JP2003525944 A5 JP 2003525944A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- aryl
- substituted
- chr
- atoms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000003118 aryl group Chemical group 0.000 description 143
- 125000001072 heteroaryl group Chemical group 0.000 description 84
- 125000000217 alkyl group Chemical group 0.000 description 75
- 125000004429 atom Chemical group 0.000 description 71
- 125000003710 aryl alkyl group Chemical group 0.000 description 56
- 125000004122 cyclic group Chemical group 0.000 description 55
- 125000005842 heteroatom Chemical group 0.000 description 52
- 125000003107 substituted aryl group Chemical group 0.000 description 50
- -1 perhaloalkyl Chemical group 0.000 description 45
- 150000001875 compounds Chemical class 0.000 description 41
- 229910052717 sulfur Inorganic materials 0.000 description 40
- 229910052760 oxygen Inorganic materials 0.000 description 36
- 229910052757 nitrogen Inorganic materials 0.000 description 29
- 229910052799 carbon Inorganic materials 0.000 description 25
- 125000002723 alicyclic group Chemical group 0.000 description 16
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 11
- 125000005647 linker group Chemical group 0.000 description 11
- 125000004437 phosphorous atom Chemical group 0.000 description 11
- 125000004432 carbon atom Chemical group C* 0.000 description 9
- 125000005843 halogen group Chemical group 0.000 description 9
- 125000002252 acyl group Chemical group 0.000 description 8
- 125000004423 acyloxy group Chemical group 0.000 description 7
- 125000003342 alkenyl group Chemical group 0.000 description 7
- 125000005200 aryloxy carbonyloxy group Chemical group 0.000 description 7
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 7
- 125000006413 ring segment Chemical group 0.000 description 7
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 6
- 125000000304 alkynyl group Chemical group 0.000 description 6
- 125000001188 haloalkyl group Chemical group 0.000 description 6
- 229910052698 phosphorus Inorganic materials 0.000 description 6
- 239000011574 phosphorus Substances 0.000 description 6
- 125000005275 alkylenearyl group Chemical group 0.000 description 5
- 125000002541 furyl group Chemical group 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 125000004939 6-pyridyl group Chemical group N1=CC=CC=C1* 0.000 description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 4
- 125000005041 acyloxyalkyl group Chemical group 0.000 description 4
- 125000005205 alkoxycarbonyloxyalkyl group Chemical group 0.000 description 4
- 125000002947 alkylene group Chemical group 0.000 description 4
- 125000006165 cyclic alkyl group Chemical group 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 125000000714 pyrimidinyl group Chemical group 0.000 description 4
- 125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- 101710099475 3'-phosphoadenosine 5'-phosphate phosphatase Proteins 0.000 description 2
- 101710196411 Fructose-1,6-bisphosphatase Proteins 0.000 description 2
- 101710186733 Fructose-1,6-bisphosphatase, chloroplastic Proteins 0.000 description 2
- 101710109119 Fructose-1,6-bisphosphatase, cytosolic Proteins 0.000 description 2
- 101710198902 Fructose-1,6-bisphosphate aldolase/phosphatase Proteins 0.000 description 2
- 208000002705 Glucose Intolerance Diseases 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 125000002877 alkyl aryl group Chemical group 0.000 description 2
- 125000006365 alkylene oxy carbonyl group Chemical group 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 201000009104 prediabetes syndrome Diseases 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 0 CCC*N(N(C)N(**)N(C)N*N)OC Chemical compound CCC*N(N(C)N(**)N(C)N*N)OC 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 125000001543 furan-2,5-diyl group Chemical group O1C(=CC=C1*)* 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 208000007345 glycogen storage disease Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 125000006362 methylene amino carbonyl group Chemical group [H]N(C([*:2])=O)C([H])([H])[*:1] 0.000 description 1
- 125000006366 methylene oxy carbonyl group Chemical group [H]C([H])([*:1])OC([*:2])=O 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18775000P | 2000-03-08 | 2000-03-08 | |
| US60/187,750 | 2000-03-08 | ||
| PCT/US2001/007452 WO2001066553A2 (en) | 2000-03-08 | 2001-03-07 | Novel aryl fructose-1,6-bisphosphatase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003525944A JP2003525944A (ja) | 2003-09-02 |
| JP2003525944A5 true JP2003525944A5 (enExample) | 2008-02-28 |
Family
ID=22690309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001565369A Withdrawn JP2003525944A (ja) | 2000-03-08 | 2001-03-07 | 新規アリールフルクトース−１，６−ビスホスファターゼ阻害剤 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US6919322B2 (enExample) |
| EP (2) | EP1607401A1 (enExample) |
| JP (1) | JP2003525944A (enExample) |
| KR (1) | KR20020079988A (enExample) |
| CN (2) | CN1699383A (enExample) |
| AT (1) | ATE350385T1 (enExample) |
| AU (2) | AU2001245532B2 (enExample) |
| BR (1) | BR0109062A (enExample) |
| CA (1) | CA2401706A1 (enExample) |
| CZ (1) | CZ20023018A3 (enExample) |
| DE (1) | DE60125734T2 (enExample) |
| HU (1) | HUP0300344A3 (enExample) |
| IL (2) | IL151248A0 (enExample) |
| MX (1) | MXPA02008722A (enExample) |
| NO (1) | NO20024240L (enExample) |
| PL (1) | PL357251A1 (enExample) |
| RU (1) | RU2002126616A (enExample) |
| SK (1) | SK12722002A3 (enExample) |
| WO (1) | WO2001066553A2 (enExample) |
| ZA (1) | ZA200207004B (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998039344A1 (en) | 1997-03-07 | 1998-09-11 | Metabasis Therapeutics, Inc. | Novel purine inhibitors of fructose-1,6-bisphosphatase |
| CZ297264B6 (cs) * | 1998-09-09 | 2006-10-11 | Metabasis Therapeutics, Inc. | Nové heteroaromatické inhibitory fruktóza-1,6-bisfosfatázy |
| US6756360B1 (en) * | 1998-12-24 | 2004-06-29 | Metabasis Therapeutics, Inc. | Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes |
| CN1740182A (zh) * | 1999-12-22 | 2006-03-01 | 症变治疗公司 | 新的双氨基化膦酸酯前药 |
| EP1607401A1 (en) | 2000-03-08 | 2005-12-21 | Metabasis Therapeutics, Inc. | Novel aryl fructose-1,6-Bisphosphatase inhibitors |
| US7563774B2 (en) * | 2000-06-29 | 2009-07-21 | Metabasis Therapeutics, Inc. | Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes |
| EP1535630A1 (en) * | 2002-07-23 | 2005-06-01 | Sankyo Company, Limited | Preventive for the onset of diabetes |
| FR2846327B1 (fr) * | 2002-10-25 | 2006-03-24 | Merck Sante Sas | Derives de n-benzodioxolyl, n-benzodioxanyl et n-benzodioxepinyl arylcarboxamides utilisables dans le traitement de dyslipidemies et compositions pharmaceutiques les contenant. |
| US7129049B2 (en) * | 2003-12-22 | 2006-10-31 | Regents Of The University Of Minnesota | Method of detecting equine glycogen storage disease IV |
| EP1778250A2 (en) * | 2004-08-18 | 2007-05-02 | Metabasis Therapeutics, Inc. | Novel thiazole inhibitors of fructose 1,6-bisphosphatase |
| BRPI0519006A2 (pt) * | 2004-12-13 | 2008-12-23 | Daiichi Sankyo Co Ltd | uso de um inibidor de fbpase, kit de uma composiÇço farmacÊutica, uso de uma preparaÇço de biguanida e um inibidor de fbpase, agente terapÊutico para diabetes melito, e, combinaÇço de agentes terapÊuticos |
| CN101115483A (zh) * | 2004-12-15 | 2008-01-30 | 第一三共株式会社 | 含有FBPase抑制剂的药物组合物 |
| EP1752450A1 (en) | 2005-08-01 | 2007-02-14 | Merck Sante | Imidazole derivatives as fructose-1,6-bisphosphatase inhibitors and pharmaceutical compositions containing them |
| CA2695583A1 (en) | 2007-08-13 | 2009-02-19 | Metabasis Therapeutics, Inc. | Novel activators of glucokinase |
| EP2058308A1 (fr) | 2007-11-12 | 2009-05-13 | Merck Sante | Dérivés de benzimidazoledihydrothiadiazinone comme inhibiteurs de fructose-1,6-biphosphatase et compositions pharmaceutiques les contenant. |
| EP2408774B1 (en) | 2009-03-20 | 2014-11-26 | Metabasis Therapeutics, Inc. | Inhibitors of diacylglycerol o-acyltransferase 1(dgat-1) and uses thereof |
| US9006568B2 (en) * | 2012-02-15 | 2015-04-14 | Phillips 66 Company | Synthesis of photovoltaic conjugated polymers |
| KR102062517B1 (ko) * | 2012-04-20 | 2020-01-06 | 바이엘 크롭사이언스 악티엔게젤샤프트 | Ｎ-시클로알킬-ｎ-［（헤테로시클릴페닐）메틸렌］-（티오）카르복사미드 유도체 |
| CN107312039B (zh) | 2012-08-30 | 2019-06-25 | 江苏豪森药业集团有限公司 | 一种替诺福韦前药的制备方法 |
| US9691986B2 (en) | 2012-12-03 | 2017-06-27 | Solarmer Energy, Inc. | Furan and selenophene derivatized benzo [1,2-b:4,5-b′] dithiophene-thienothiophene based conjugated polymers for high-efficiency organic solar cells |
| EP3078378B1 (en) | 2015-04-08 | 2020-06-24 | Vaiomer | Use of factor xa inhibitors for regulating glycemia |
| US9911919B2 (en) | 2015-10-01 | 2018-03-06 | Phillips 66 Company | Process of manufacturing an electron transport material |
| US10312448B2 (en) | 2015-10-01 | 2019-06-04 | Phillips 66 Company | Process of manufacturing an electron transport material |
| WO2017058406A1 (en) | 2015-10-01 | 2017-04-06 | Phillips 66 Company | Formation of films for organic photovoltaics |
| US10418555B2 (en) | 2015-10-01 | 2019-09-17 | Phillips 66 Company | Formation of films for organic photovoltaics |
| US9905769B2 (en) | 2015-10-01 | 2018-02-27 | Phillips 66 Company | Process of manufacturing an electron transport material |
| CN109715637B (zh) | 2016-07-22 | 2022-04-05 | 百时美施贵宝公司 | 葡萄糖激酶激活剂及其使用方法 |
| CN111116647B (zh) * | 2019-12-02 | 2021-08-24 | 西安电子科技大学 | 一种具有hdac抑制活性的磷酸类化合物及其制备方法与用途 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL72851C (enExample) * | 1950-10-31 | 1900-01-01 | ||
| US2683168A (en) * | 1950-12-22 | 1954-07-06 | California Research Corp | Preparation of organo phosphonyl chlorides |
| US3524846A (en) | 1967-06-02 | 1970-08-18 | Syntex Corp | Process for the didealkylation of phosphonate esters |
| GB2043073B (en) * | 1979-02-13 | 1983-05-11 | Symphar Sa | Mono-and diphosphonate compounds |
| US4640701A (en) * | 1984-04-17 | 1987-02-03 | Ciba-Geigy Corporation | Herbicidal phosphonic acid and phosphinic acid derivatives |
| US4746653A (en) * | 1986-02-28 | 1988-05-24 | Ciba-Geigy Corporation | Certain hetero phosphonic acid derivatives of 2-piperidine or 2-tetrahydropyridinecarboxylates and esters thereof which are useful for the treatment of disorders responsive to blockade of the NMDA receptor in mammals |
| US4968788A (en) | 1986-04-04 | 1990-11-06 | Board Of Regents, The University Of Texas System | Biologically reversible phosphate and phosphonate protective gruops |
| EP0243173B1 (en) * | 1986-04-24 | 1991-06-26 | Fujisawa Pharmaceutical Co., Ltd. | New diphosphonic acid compounds, processes for the preparation thereof and pharmaceutical composition comprising the same |
| US5091552A (en) | 1986-06-30 | 1992-02-25 | Board Of Regents, The University Of Texas System | Novel antitumor aldophosphamide analogs |
| US5045557A (en) * | 1987-03-20 | 1991-09-03 | Schering Agrochemicals Ltd. | Imidazable fungicides and use thereof |
| US4968790A (en) | 1988-08-12 | 1990-11-06 | American Cyanamid Company | Antidiabetic phosphates |
| US4943629A (en) | 1988-08-12 | 1990-07-24 | American Cyanamid Company | Antidiabetic alpha-substituted phosphonates |
| US5658889A (en) | 1989-01-24 | 1997-08-19 | Gensia Pharmaceuticals, Inc. | Method and compounds for aica riboside delivery and for lowering blood glucose |
| JPH03504728A (ja) | 1989-01-24 | 1991-10-17 | ジェンシア・ファーマシュウティカルズ，インコーポレイテッド | Ａｉｃａリボシドの放出および血液グルコースの低減のための化合物および方法 |
| ES2083580T3 (es) | 1990-06-13 | 1996-04-16 | Arnold Glazier | Profarmacos de fosforo. |
| US5157027A (en) | 1991-05-13 | 1992-10-20 | E. R. Squibb & Sons, Inc. | Bisphosphonate squalene synthetase inhibitors and method |
| US5208235A (en) * | 1992-03-10 | 1993-05-04 | E. R. Squibb & Sons, Inc. | Indole- and benzimidazole-substituted imidazole derivatives |
| US5278153A (en) * | 1992-05-18 | 1994-01-11 | E. R. Squibb & Sons, Inc. | Aryl and heteroaryl (phosphinylmethyl)phosphonate squalene synthetase inhibitors and method |
| WO1994007867A1 (en) * | 1992-09-28 | 1994-04-14 | Pfizer Inc. | Substituted pyrimidines for control of diabetic complications |
| DE69426904T2 (de) | 1993-06-29 | 2001-10-11 | Mitsubishi Chemical Corp., Tokio/Tokyo | Phosphonat-Nukleotid Ester-Derivate |
| ATE486882T1 (de) | 1993-09-17 | 2010-11-15 | Gilead Sciences Inc | Nukleotidanaloge |
| US6011049A (en) | 1997-02-19 | 2000-01-04 | Warner-Lambert Company | Combinations for diabetes |
| AU6691798A (en) | 1997-03-07 | 1998-09-22 | Metabasis Therapeutics, Inc. | Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase |
| DE69819311T2 (de) * | 1997-03-07 | 2004-07-29 | Metabasis Therapeutics Inc., San Diego | Neue benzimidazol inhibitoren der fructose-1,6-bisphosphatase |
| WO1998039344A1 (en) * | 1997-03-07 | 1998-09-11 | Metabasis Therapeutics, Inc. | Novel purine inhibitors of fructose-1,6-bisphosphatase |
| US6312662B1 (en) | 1998-03-06 | 2001-11-06 | Metabasis Therapeutics, Inc. | Prodrugs phosphorus-containing compounds |
| CA2322487C (en) | 1998-03-06 | 2010-07-20 | Metabasis Therapeutics, Inc. | Novel prodrugs for phosphorus-containing compounds |
| EP1070084A4 (en) | 1998-03-16 | 2001-09-12 | Ontogen Corp | PIPERAZINE AS INHIBITORS OF FRUKTOSE-1,6-BISPHOSPHATASE (FBPASE) |
| CZ297264B6 (cs) | 1998-09-09 | 2006-10-11 | Metabasis Therapeutics, Inc. | Nové heteroaromatické inhibitory fruktóza-1,6-bisfosfatázy |
| DE19843383A1 (de) * | 1998-09-22 | 2000-03-30 | Hassan Jomaa | Phosphororganische Verbindungen und ihre Verwendung |
| WO2000038666A2 (en) * | 1998-12-24 | 2000-07-06 | Metabasis Therapeutics, Inc. | A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES |
| US6756360B1 (en) * | 1998-12-24 | 2004-06-29 | Metabasis Therapeutics, Inc. | Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes |
| SK12442001A3 (sk) * | 1999-03-05 | 2002-06-04 | Metabasis Therapeutics, Inc. | Cyklické fosforamidáty, spôsob ich prípravy a farmaceutické kompozície, ktoré ich obsahujú |
| CN1740182A (zh) * | 1999-12-22 | 2006-03-01 | 症变治疗公司 | 新的双氨基化膦酸酯前药 |
| ATE385421T1 (de) | 2000-01-21 | 2008-02-15 | Novartis Pharma Gmbh | Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica |
| EP1607401A1 (en) | 2000-03-08 | 2005-12-21 | Metabasis Therapeutics, Inc. | Novel aryl fructose-1,6-Bisphosphatase inhibitors |
| CY2010012I2 (el) * | 2000-05-25 | 2020-05-29 | Novartis Ag | Μιμητικα θρομβοποιητινης |
| US7563774B2 (en) * | 2000-06-29 | 2009-07-21 | Metabasis Therapeutics, Inc. | Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes |
| CN101301294A (zh) | 2000-07-06 | 2008-11-12 | 症变治疗公司 | Fbp酶抑制剂与抗糖尿病药联合用于治疗糖尿病 |
| EP1778250A2 (en) | 2004-08-18 | 2007-05-02 | Metabasis Therapeutics, Inc. | Novel thiazole inhibitors of fructose 1,6-bisphosphatase |
-
2001
- 2001-03-07 EP EP05015039A patent/EP1607401A1/en not_active Withdrawn
- 2001-03-07 CN CNA2005100720821A patent/CN1699383A/zh active Pending
- 2001-03-07 HU HU0300344A patent/HUP0300344A3/hu unknown
- 2001-03-07 EP EP01918456A patent/EP1265907B9/en not_active Expired - Lifetime
- 2001-03-07 BR BR0109062-3A patent/BR0109062A/pt not_active Application Discontinuation
- 2001-03-07 JP JP2001565369A patent/JP2003525944A/ja not_active Withdrawn
- 2001-03-07 CN CNA018090214A patent/CN1516705A/zh active Pending
- 2001-03-07 CA CA002401706A patent/CA2401706A1/en not_active Abandoned
- 2001-03-07 US US09/801,933 patent/US6919322B2/en not_active Expired - Lifetime
- 2001-03-07 MX MXPA02008722A patent/MXPA02008722A/es active IP Right Grant
- 2001-03-07 PL PL01357251A patent/PL357251A1/xx not_active Application Discontinuation
- 2001-03-07 SK SK1272-2002A patent/SK12722002A3/sk unknown
- 2001-03-07 WO PCT/US2001/007452 patent/WO2001066553A2/en not_active Ceased
- 2001-03-07 KR KR1020027011737A patent/KR20020079988A/ko not_active Ceased
- 2001-03-07 CZ CZ20023018A patent/CZ20023018A3/cs unknown
- 2001-03-07 AT AT01918456T patent/ATE350385T1/de not_active IP Right Cessation
- 2001-03-07 DE DE60125734T patent/DE60125734T2/de not_active Expired - Fee Related
- 2001-03-07 RU RU2002126616/04A patent/RU2002126616A/ru unknown
- 2001-03-07 AU AU2001245532A patent/AU2001245532B2/en not_active Ceased
- 2001-03-07 AU AU4553201A patent/AU4553201A/xx active Pending
- 2001-03-07 IL IL15124801A patent/IL151248A0/xx active IP Right Grant
-
2002
- 2002-08-14 IL IL151248A patent/IL151248A/en not_active IP Right Cessation
- 2002-08-30 ZA ZA200207004A patent/ZA200207004B/en unknown
- 2002-09-05 NO NO20024240A patent/NO20024240L/no not_active Application Discontinuation
-
2005
- 2005-01-25 US US11/043,859 patent/US7371739B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2002126616A (ru) | Новые арильные ингибиторы фруктозо-1, 6-бисфосфатазы | |
| JP2002524463A5 (enExample) | ||
| AU2020346908B2 (en) | Antiviral prodrugs and formulations thereof | |
| RU2008127750A (ru) | Антивирусные нуклеозиды | |
| JP2006511484A5 (enExample) | ||
| JP2003519154A5 (enExample) | ||
| JP2005529923A5 (enExample) | ||
| JP2005519916A5 (enExample) | ||
| JP2019519598A5 (enExample) | ||
| JP2020528889A5 (enExample) | ||
| CN105051017A (zh) | 用于hbv组装效应剂的替代用途 | |
| JP2022533069A5 (enExample) | ||
| RU97116714A (ru) | Композиция селективных ингибиторов вирусных или бактериальных нейраминидаз (варианты), способ лечения или профилактики заболевания гриппом, способ лечения или профилактики вирусных заболевания (варианты) | |
| RU2016122908A (ru) | Соединения дигидропиримидина и их применение в фармацевтических препаратах | |
| JPH03504969A (ja) | ピリミジン誘導体 | |
| JP2025505200A5 (enExample) | ||
| KR20100084647A (ko) | 세라마이드 유도체로 다낭성 신장질환을 치료하는 방법 | |
| RU2012122615A (ru) | Новые соединения в качестве модуляторов рецепторов с терапевтическим действием | |
| JP2022137237A5 (enExample) | ||
| JP2019531346A5 (enExample) | ||
| EP2123620A1 (en) | {F-19}-labeled L-Glutamic acid and L-Glutamine derivative (III), use thereof and method for obtaining them | |
| JP2023164918A5 (enExample) | ||
| JP2025505647A5 (enExample) | ||
| JP2003515523A5 (enExample) | ||
| RU97113367A (ru) | Производные нейраминовой кислоты, их получение и применение в медицине |